Foresight Biotherapeutics, a New York company developing new therapies to treat eye and ear disorders, has raised $2 million, according to an SEC filing. Foresight’s technology platform, called Povidone-Iodine (PVP-I), allows a well-known antiseptic to be formulated in different ways. The company’s lead experimental compound is being tested in a form of conjunctivitis. The company was co-founded by Jason Stein and Michael Weiser, who are also the founders of Actin Biomed, a healthcare investment firm.
Author: Arlene Weintraub
Arlene is an award-winning journalist specializing in life sciences and technology. She was previously a senior health writer based out of the New York City headquarters of BusinessWeek, where she wrote hundreds of articles that explored both the science and business of health. Her freelance pieces have been published in USA Today, US News & World Report, Technology Review, and other media outlets. Arlene has won awards from the New York Press Club, the Association of Health Care Journalists, the Foundation for Biomedical Research, and the American Society of Business Publication Editors. Her book about the anti-aging industry, Selling the Fountain of Youth, was published by Basic Books in September 2010.
View all posts by Arlene Weintraub
